Daily Chart

Send a Tweet

$NVS
#Novartis Ag-sponsored Adr
NVS
Novartis Ag-sponsored Adr
Look for:
NVS
Pre-Market Movers: $NVO,$FCL,$PCZ,$GSK,$ERTS,$HBC,$DDR,$DB,$GFA,$NVS...more
NVS
Novartis $NVS in-licenses a mid-to-late-stage experimental hepatitis C drug from a private Swiss co. Gains exclusive WW rights,except Japan.
NVS
Monday February 8 2010 MACD Sell Signal $ALXN $BAP $GILD $MCD $ROST $NVS $PETD $PII $LKFN $NTY #economics
NVS
@drpdtapp yes $NVS have Afinitor and $GSK have pazopanib. There are 6 approved in renal cc now
NVS
Getting ready for exclusive interview w/Roche CEO Severin Schwan @ 7:30a ET-ish on Squawk Box. $RHHBY $NVS (@mhuckman)
NVS
Getting ready for exclusive interview w/Roche CEO Severin Schwan @ 7:30a ET-ish on Squawk Box. Crew tweaking lights now. $RHHBY $NVS
NVS
Allergan’s Looking Real Pretty Right Now http://cnbc.com/id/35238576 $ABT $ACL $AGN $NVS #StockPicks #StockMarket
NVS
RT@MhuckmanRoche CEO Severin Schwan live 2mrw @ 7:30a ET-ish on "Squawk Box." 1st CNBC U.S. interview since buying Genentech. $RHH
NVS
Roche CEO Severin Schwan live 2mrw @ 7:30a ET-ish on "Squawk Box." 1st CNBC U.S. interview since buying Genentech. $RHHBY $NVS
NVS
Pfizer Earnings By the Numbers http://cnbc.com/id/35196988 $AMGN $BIIB $GENZ $GILD $MRK $NVS $PFE $WAT #StockMarket
NVS
$NVS $CSBTF Hypertension Market Will Be Constrained Through 2018 by Pipeline Containing Few Novel Emerging Therapies http://bit.ly/c3boXR
NVS
Is Genentech/Roche turning a blind eye to a marketing/PR opportunity for Lucentis/Avastin? Vote in the poll. http://bit.ly/9VSjxq $NVS
NVS
RT @adamfeuerstein: @mhuckman: Kaiser "real-world" study:Avastin = Lucentis for AMD. $NVS $RHHBY Genentech: Only L proven safe,eff
NVS
RT @mhuckman: BREAKING Kaiser "real-world" study:Avastin works just as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucent
NVS
RT @mhuckman: Kaiser "real-world" study:Avastin works as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucentis proven safe
NVS
RT @mhuckman: BREAKING Kaiser "real-world" study:Avastin works just as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucent
NVS
BREAKING Kaiser "real-world" study:Avastin works just as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucentis proven safe
NVS
RT @mhuckman: FDA OKs using Glaxo's Tykerb w/Novartis' Femara for certain type advanced breast cancer in post-menopausal women. $GSK $NVS.
NVS
RT @mhuckman: FDA OKs using Glaxo's Tykerb w/Novartis' Femara for certain type advanced breast cancer in post-menopausal women. $GSK $NVS.
NVS
FDA OKs using Glaxo's Tykerb w/Novartis' Femara for certain type advanced breast cancer in post-menopausal women. $GSK $NVS.




Novartis Ag-sponsored Adr - NVS Insiders

No Insiders

We have no insiders for Novartis Ag-sponsored Adr right now.

Know someone who is an insider on Novartis Ag-sponsored Adr?
Let us know.

Novartis Ag-sponsored Adr - NVS information

...
133,000 Employees
Last Reported Date: 10/28/14
Founded in 1895
Last $96.87 USD
Change Today +0.03 / 0.03%
Volume 1.9M
As of 8:04 PM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

novartis ag-sponsored adr (NVS) Snapshot

Open
$98.01
Previous Close
$96.84
Day High
$98.06
Day Low
$96.71
52 Week High
01/20/15 - $102.59
52 Week Low
02/4/14 - $77.90
Market Cap
262.1B
Average Volume 10 Days
4.1M
EPS TTM
--
Shares Outstanding
2.7B
EX-Date
02/27/14
P/E TM
--
Dividend
$2.76
Dividend Yield
2.85%
Request Investor Kit
NVS:US Advanced Stock Chart

novartis ag-sponsored adr (NVS) Related Bloomberg News

Actavis Blood Pressure Pill Not Backed by U.S. Advisers
Amazon, Oracle, Toshiba, Cipla: Intellectual Property
Fed Taper Question Keeps U.S. Corporate Bond Sales Below Average
Novartis Jury Awards $10.45 Million for Drug, Lawyer Says
Novartis’s Alcon Wins Bid to Block Apotex’s Generic Patanol

novartis ag-sponsored adr (NVS) Related News

Australia's CSL Wants to Make Your Flu Shots
Botox Maker Plans Deep Job Cuts During Takeover Fight
Who Should Pay the Bill for Wonder Drugs?
Big Pharma's Favorite Prescription: Higher Prices
[addPosition2]

novartis ag-sponsored adr (NVS) Key Developments

Novartis AG's Bexsero Vaccine Approved by FDA for Prevention of Meningitis B

Novartis announced that the US Food and Drug Administration (FDA) has granted accelerated approval of Bexsero® (Meningococcal Group B Vaccine [recombinant, adsorbed]) for active immunization to prevent invasive meningococcal disease caused by serogroup B (also known as meningitis B) in adolescents and young adults from 10 years through 25 years of age. Bexsero is the only meningitis B vaccine approved in the US with a two-dose regimen and a flexible dosing schedule1. As part of the accelerated approval process, Novartis will complete its ongoing studies to confirm the effectiveness of Bexsero against diverse serogroup B strains. In Phase II and Phase III studies, Bexsero demonstrated a protective immune response in adolescents and young adults after two doses. Bexsero also offers a flexible dosing schedule, with the first and second doses administered at least one month apart. The tolerability profile of Bexsero was also demonstrated as part of a US Centers for Disease Control and Prevention (CDC)-sponsored clinical trial conducted in more than 15,000 individuals at Princeton University and the University of California, Santa Barbara (UCSB) during meningitis B outbreaks on these college campuses. The safety data from the CDC clinical trial are consistent with results observed in previous studies.

Novartis Eyes Acquisitions

Novartis AG (SWX:NOVN) intends to make acquisitions. Joe Jimenez, Chief Executive Officer of the company said Novartis would look at bolt-on acquisitions. "What we've done at Novartis is put ourselves in a position where we can participate in future M&A but we don't have to," he said.

Novartis Announces FDA Approval for First IL-17A Antagonist Cosentyx (Secukinumab) for Moderate-To-Severe Plaque Psoriasis Patients

Novartis announced the US Food and Drug Administration (FDA) has approved Cosentyx™ (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy (a drug that is absorbed into the bloodstream and distributed to all parts of the body) or phototherapy (light therapy). Cosentyx is the first approved psoriasis medication to selectively bind to IL-17A and inhibit its interaction with the IL-17 receptor. The approval is based on the efficacy and safety outcomes from 10 Phase II and III studies, including over 3,990 patients with moderate-to-severe plaque psoriasis, which demonstrated that Cosentyx resulted in clear or almost clear skin in the majority of patients and had an acceptable safety profile. The Phase III clinical program included four placebo-controlled studies which examined Cosentyx 300 mg and 150 mg in patients with moderate-to-severe plaque psoriasis. In these studies, Cosentyx met all primary and key secondary endpoints, including Psoriasis Area and Severity Index (PASI) 75 and 90 and Investigator's Global Assessment modified 2011 (IGA) 0/1 responses, showing significant skin clearance at Week 12. PASI measures the redness, scaling and thickness of psoriatic plaques, and the extent of involvement in each region of the body. Treatment efficacy is assessed by the reduction of the score from baseline (a 75% reduction is known as PASI 75 and a 90% reduction is known as PASI 90). PASI 90 is a higher standard of skin clearance compared to PASI 75.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVS:US $96.87 USD +0.03

NVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $105.54 USD +0.40
Merck & Co Inc $62.49 USD -0.10
Nestle SA SFr.68.40 CHF +2.10
Pfizer Inc $32.45 USD -0.36
Procter & Gamble Co/The $90.08 USD -1.54
 

Industry Analysis

NVS

Industry Average

Valuation NVS Industry Range
Price/Earnings 23.6x
Price/Sales 3.9x
Price/Book 3.3x
Price/Cash Flow 24.4x
TEV/Sales 3.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Novartis Ag-sponsored Adr - NVS news

3 Mega-Cap Dividend Stock Ideas

Quote:
Read article

US doctor pleads guilty in securities case

Keywords: US doctor pleads guilty in securities case, nvs, pe-and-hedgefunds
Quote:
Read article

Awaiting Novartis acquisition, biotech firm Proteon raises $15.2M

Quote:
Read article

Will Investors Regret Leaving The US?

Keywords: ETFs,Investing,Markets,Stocks,Business,Exchange-traded fund,Forbes,IShares,Research and Analysis,Shares outstanding,Trade
Quote:
Read article

LEAD 1-Nestlé porté par la croissance dans les pays émergents

Quote:
Read article

UPDATE 1-Vectura extends VR315 deal with Sandoz to new areas

Keywords: United States, Will Waterman
Quote:
Read article

Momenta's earnings rise on market grab from Sanofi

Quote:
Read article

[$$] Novartis' MS Pill Questioned by U.K. Regulator

Quote:
Read article

9 Swiss Stocks That May Be a Haven

Quote:
Read article

Advisers steer clients to safer havens in stormy market

Keywords: Greece, Italy, Switzerland, RichardSatran, S&P 500
Quote:
Read article

Vanda Pharmaceuticals reports loss

Quote:
Read article

Swiss stocks - Factors to watch on Aug 5

Quote:
Read article

FDA: Generic biotech drugs require paradigm shift

Keywords: Israel, United States, Michele Gershberg, Phil Berlowitz
Quote:
Read article

UPDATE 2-Vectura gets new U.S. partner for copy of lung drug

Keywords: United States, Andrew Callus
Quote:
Read article

UPDATE 1-Vectura strikes new U.S. deal for lung drug VR315

Keywords: United States
Quote:
Read article

UPDATE 1-Finnish drug maker Orion Q2 meets forecast

Keywords: Switzerland, Jane Merriman
Quote:
Read article

Vanda aims for Argentina

Quote:
Read article

Buyout firms to bid for GSK drugs portfolio-sources

Keywords: Britain, Jane Merriman
Quote:
Read article

PDL posts bigger 2Q profit on lower legal costs

Keywords: PDL posts bigger 2Q profit on lower legal costs, nvs,pdli, earnings
Quote:
Read article

Flu "super antibody" may bring universal shot closer

Quote:
Read article
Stocktweeting is not a financial advisor, and in no way recommends the purchase of any stock or advise on the suitability of any trade or investment.
Stock trading and investing can cause loss of capital, and you should always consult with a professional financial advisor before trading or investing.

This website is a service of the HagensMedia ad network. For advertising please visit http://www.hagensmedia.com - Copyright 2011-2012.